Vol 8, Supplement 1 (March 05, 2019): Hepatobiliary Surgery and Nutrition (3rd Asia-Pacific Cholangiocarcinoma Conference)

Foreword

Foreword
Flavio Rocha, Li-Tzong Chen

Speaker Abstracts

AB001. Keynote. Development of effective immune checkpoint cancer therapy
Mien-Chie Hung
AB002. S1-1. Recent adventure in cholangiocarcinoma—focus on molecular profiling
Yun Yen
AB003. S1-2. Genetic and environmental risk factors for cholangiocarcinoma (CCA)
Tatsuhiro Shibata
AB004. S1-3. Biliary imaging in diagnosis and staging
Bang-Bin Chen
AB005. S1-4. What is the best approach for biopsy and stenting hilar cholangiocarcinoma?
Jeffrey H. Lee
AB006. S1-5. What is the best approach for biopsy and stenting hilar cholangiocarcinoma?
Wei-Chih Liao
AB007. S2-1. Liver-directed therapy for cholangiocarcinoma
Sean P. Cleary
AB008. S2-2. Surgical approach to intrahepatic cholangiocarcinoma
Shishir K. Maithel
AB009. S2-3. Surgical approach to hilar cholangiocarcinoma
Michael A. Choti
AB010. S2-4. Hepatopancreatoduodenectomy (HPD) for cholangiocarcinoma
Masato Nagino
AB011. S2-5. Liver transplantation for cholangiocarcinoma
Keri E. Lunsford
AB012. S3A-1. The role of adjuvant therapy in biliary tract tumors
John N. Primrose
AB013. S3A-2. The future potential of immunotherapy in biliary tract cancer
Nilofer S. Azad
AB014. S3A-3. Precision medicine on the horizon for cholangiocarcinoma
Lipika Goyal
AB015. S3B-1. An international collaborative of clinical nursing practice evidence-based guidelines for care of patients with cholangiocarcinoma
Susan Acquisto
AB016. S3B-2. Cholangitis: nursing assessment and management
Wen-Tzu Chiu
AB017. S3B-3. Guidelines for care of the patient receiving chemotherapy
Renuka V. Iyer
AB018. S3B-4. Complications of radiation therapy: key concepts for patient education
Lorraine Drapek
AB019. S3B-5. Living well with cancer—a personalized and need-based cancer care
Yeur-Hur Lai
AB020. S3B-6. Nutrition care in patients with cancer
Pei-Hung Chang
AB021. S4-1. Intra-hepatic cholangiocarcinoma: how to choose among different loco-regional therapies?
Bruno C. Odisio
AB022. S4-2. Role of radiotherapy in cholangiocarcinoma
Jinsil Seong
AB023. S4-3. Down-staging locally advanced disease
Rachna T. Shroff
AB024. S4-4. Percutaneous transhepatic portal vein embolization and evaluation of future liver remnant
Ta-Sen Yeh
AB025. S5A-1. Immune biomarkers of cholangiocarcinoma: microsatellite instability and EBV
Ming-Huang Chen
AB026. S5A-2. The role of TS-1 in cholangiocarcinoma
Nai-Jung Chiang
AB027. S6-1. Biomarkers in cholangiocarcinoma
Chien-Feng Li
AB028. S6-2. Drugs and targets in development
Ming-Huang Chen
AB029. S6-3. Clinical trials incorporating translational targets
Takuji Okusaka
AB030. S7-1. How to use large databases in research
Chun-Ying Wu
AB031. S7-2. Consolidating the treatment guidelines of chemotherapy for cholangiocarcinoma between the East and West
Junji Furuse
AB032. S7-3. Introduction of Taiwan Liver Cancer Network
Shiu-Feng Huang, Il-Chi Chang, Pei-Jer Chen, Chi-Ling Chen, Tseng-Chang Yen, Yun-Fan Liaw
AB033. P-01. Andrographolide (AP1) inhibits cholangiocarcinoma cell invasion in vitro model
Anyaporn Sawasdichai Chailert, Jomnarong Lertsuwan, Nathapol Tasnawijitwong, Tawit Suriyo, Nuchanart Rukadilok, Nuntanit Pholphana, Kevin Gaston, Padma-Sheela Jayaraman, Jutamaad Satayavivad

Poster Abstracts

AB034. P-02. Depletion of SRSF1 inhibits proliferation, promotes apoptosis and changes cellular proteome of cholangiocarcinoma cells
Pawee Tangwiriyarotkul, Phichamon Phetchahwang, Sucheewin Krobthong, Sittiruk Roytrakul, Sopit Wongkham, Worasak Kaewkong
AB035. P-03. Explore the mutational landscape and immune profile of EBV-associated lymphoepithelioma-like cholangiocarcinoma
Nai-Jung Chiang, Ming-Huang Chen, Ming-Han Tsai, Hung-Wen Tsai, Li-Tzong Chen, Yan-Shen Shan
AB036. P-04. The upregulation of Oct4 in acidic extracellular pH is associated with gemcitabine resistance in cholangiocarcinoma cell lines
Phatchareeporn Choodetwattana, Siriporn Proungvitaya, Patcharee Jearanaikoon, Temduang Limpaiboon
AB037. P-05. Evaluation of infrared spectral signature associated with pathology as biomarker for cancer progression in cholangiocarcinoma
Patcharaporn Tippayawat, Molin Wongwattanakul, Parichart Boueroy, Chariya Hahnvajanawong, Tidarat Boonmars, Bayden Wood, Philip Heraud, Patcharee Jearanaikoon
AB038. P-06. Tumor-infiltrating CD8+ lymphocytes of as a prognostic factor of intrahepatic cholangiocarcinoma
Thanawoot Yothagaree, Prakasit Sa-Ngiamwibool, Supinda Koonmee, Chawalit Pairojkul
AB039. P-07. Elevated expression of the key components of polycomb repressive complex 2 is associated with poorer survival outcome in cholangiocarcinoma
Wiphawan Wasenang, Anucha Puapairoj, Chatri Settasatian, Siriporn Proungvitaya, Temduang Limpaiboon
AB040. P-08. FOENIX-CCA2: a phase 2 study of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements
Junji Furuse, Lipika Goyal, Rastsilav Bahleda, Juan Valle, Markus Moehler, Do-Youn Oh, Heung-Moon Chang, Robin Kate Kelley, Milind Javle, Mitesh Borad, Li-Tzong Chen, Nataliya Uboha, Heinz-Josef Klümpen, Peter J. O’Dwyer, Daneng Li, Chigusa Morizane, Jerry Huang, John A. Bridgewater
AB041. P-09. Neoadjuvant chemotherapy with portal vein embolization for initially unresectable hilar cholangiocarcinoma—a case report
Chun-Yi Tsai, Tsung-Han Wu, Chien-Ming Chen, Tze-Chin Chen, Ta-Sen Yeh
AB042. P-10. Initial surgical experience for hilar bile duct cancer by incorporating major extended hemihepatectomy including extrahepatic bile duct resection without the aid of portal vein embolization
Chiah-Yang Chai
AB043. P-11. Autoantibody screening in sera of patients with cholangiocarcinoma by serological proteomic approach
Mohammad Zahid Mustafa, Zunera Tanveer, Eric Ballot
AB044. P-12. Phase 1 study of hepatic arterial infusion (HAI) therapy with floxuridine (FUDR) combined with systemic gemcitabine and oxaliplatin in patients with locally advanced intrahepatic cholangiocarcinoma (ICC)
Patrick Grierson, Aabha Oza, Maria Doyle, Ryan Fields, William Hawkins, Chet Hammill, Andrea Wang-Gillam, Manik Amin, Katrina Pedersen, Kian-Huat Lim, Ashley Morton, Christine Cordova, Kathryn Fowler, Benjamin Tan, William Chapman
AB045. P-13. Genomic heterogeneity between Asian and Western intrahepatic cholangiocarcinoma
Reham Abdel-Wahab, Siqin Liu, Jingyu Cao, Jing Hu, Funda Meric-Bernstam, Junjie Xu, Qiang Li, Maolin Yan, Yujie Feng, Jianzhen Lin, Songhui Zhao, Jian Wang, Kai Wang, Mitesh J. Borad, Milind Javle, Haitao Zhao
AB046. P-14. TREETOPP: a phase 2/3 study of varlitinib plus capecitabine versus placebo plus capecitabine as second-line treatment in patients with advanced or metastatic biliary tract cancers (BTCs)
Milind M. Javle, Do-Youn Oh, Masafumi Ikeda, Shukui Qin, Wei-Peng Yong, Yee Chao, Nicola McIntyre, Chih-Yi Hsieh, Lilian Chow, Alyssa Chang, Mark McHale, Bertil Lindmark
AB047. P-15. Using an integrated microfluidic platform to explore circulating tumor cells in cholangiocarcinoma
Nai-Jung Chiang, Priya Gopinathan, Shang-Cheng Hung, Gwo-Bin Lee, Yan-Shen Shan
AB048. P-16. Molecular profiling of intrahepatic cholangiocarcinoma in Taiwan using targeted next-generation sequencing
Nai-Jung Chiang, Chien-Tsung Liu, Kun-Huei Yeh, Jen-Shi Chen, Ming-Huang Chen, Li-Tzong Chen
AB049. P-17. A phase II study of HDAC inhibition to sensitize to immunotherapy in advanced cholangiocarcinoma
Marina Baretti, Rosalind Walker, Jennifer Durham, Brian Christmas, Leslie Cope, Elizabeth M. Jaffee, Nilofer S. Azad
AB050. P-18. Rare adenocarcinoma arising from mucinous cystic neoplasm of liver: case report and literature review
Chia-Chun Hung, Hsiang-Lin Lee
AB051. P-19. A phase II study of infigratinib (BGJ398) in previously-treated advanced cholangiocarcinoma containing FGFR2 fusions
Milind Javle, R. Kate Kelley, Sameek Roychowdhury, Karl Heinz Weiss, Ghassan K. Abou-Alfa, Teresa Macarulla, Saeed Sadeghi, Dirk Waldschmidt, Andrew X. Zhu, Lipika Goyal, Mitesh Borad, Wei Peng Yong, Ivan Borbath, Anthony El-Khoueiry, Philip Philip, Susan Moran, Yining Ye, Mary Ising, Nancy Lewis, Tanios Bekaii-Saab
AB052. P-20. Phase 2, open-label study of second-line M7824 treatment in patients with locally advanced or metastatic biliary tract cancer
Mitesh Borad, Milind Javle, Junji Furuse, Chih-Hung Hsu, Markus Moehler, Do-Youn Oh, Joon Oh Park, Lin Shen, Juan Valle, Meng Li, Christoph Helwig, John Bridgewater
AB053. P-21. M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor β (TGF-β) and PD-L1, in Asian patients with pretreated biliary tract cancer (BTC): efficacy by BTC subtype
Changhoon Yoo, Do-Youn Oh, Hye Jin Choi, Masatoshi Kudo, Makoto Ueno, Shunsuke Kondo, Li-Tzong Chen, Motonobu Osada, Christoph Helwig, Isabelle Dussault, Masafumi Ikeda
AB054. P-22. An international collaborative of Clinical Nursing Practice Guidelines for care of patients with cholangiocarcinoma
Lorraine Drapek, Susan Acquisto, Renuka Iyer
AB055. P-23. The impact of perioperative CA19-9 change on the survival and recurrence patterns after adjuvant chemoradiotherapy in extrahepatic cholangiocarcinoma
Byoung Hyuck Kim, Eunji Kim, Kyubo Kim, Jin-Young Jang, Sun Whe Kim, Do-Youn Oh, Eui Kyu Chie
AB056. P-24. Characterization of cholangiocarcinoma cells by Fourier transform infrared spectral pattern
Molin Wongwattanakul, Sirinart Chio-Srichan, Chanvit Leelayuwat, Temduang Limpaiboon, Philip Heraud, Patcharee Jearanaikoon
AB057. P-25. Clinicopathologic features of intraductal tubulopapillary neoplasms of the bile duct
Janelle Rekman, Russell Dorer, Morgan Bonds, George Baison, Flavio Rocha
AB058. P-26. Utility of cholangioscopy-targeted biopsy for diagnosis of biliary neoplasms: experiences from referral hospitals in Eastern and Western countries
Phonthep Angsuwatcharakon, Osman Ahmed, Jeerawat Maytapa, William Ross, Brian Weston, Wiriyaporn Ridtitid, Pradermchai Kongkam, Rungsun Rerknimitr, Jeffrey H. Lee
AB059. P-28. Is cholangiocarcinoma the only concern in western adult patients with choledochal cyst (CC) disease and anomalous pancreaticobiliary junction (APBJ)?
George N. Baison, Morgan M. Bonds, Janelle F. Rekman, Flavio G. Rocha, Scott W. Helton, Richard A. Kozarek
AB060. P-31. Complete response to immunotherapy in cholangiocarcinoma with peritoneal metastases and high PD-L1 expression: a case report
Yung-Yeh Su, Nai-Jung Chiang, Yih-Jyh Lin, Yan-Shen Shan, Li-Tzong Chen
AB061. P-32. Multicenter, randomized phase II trial of S-1, leucovorin, oxaliplatin and gemcitabine (SLOG) in chemo-naïve advanced biliary tract cancer: a Taiwan Cooperative Oncology Group study
Jen-Shi Chen, Li-Yuan Bai, Ming-Huang Chen, Nai-Jung Chiang, Chiun Hsu, Shih-Hung Yang, Yung-Yeh Su, Yan-Shen Shan, Li-Tzong Chen
AB062. P-33. Efficacy and safety of varlitinib, a reversible pan-HER tyrosine kinase inhibitor, in combination with platinum-based regimens in biliary tract cancers: a pooled analysis from three phase 1 studies
Aaron C. Tan, Aaron C. Tan, Do-Youn Oh, Yee Chao, Chih-Yi Hsieh, Wei-Ling Chang, Fenny Isanto, Ying-Chen Chen, Mark McHale, Bertil Lindmark, Matthew C. H. Ng
AB063. P-34. A multicenter, phase 1b/2 study of varlitinib plus gemcitabine and cisplatin (gem/cis) for treatment naïve advanced or metastatic biliary tract cancer (BTC)
Do-Youn Oh, Wei-Peng Yong, Li-Tzong Chen, Ji-Won Kim, Alex Yuang-Chi Chang, Jin Hyun Park, Chih-Yi Hsieh, Hsuan-Jen Shih, Nicola McIntyre, Ying-Chen Chen, Wei-Ling Chang, Mark McHale, Bertil Lindmark
AB064. P-35. Quantitative magnetic resonance cholangiopancreatography applications in primary sclerosing cholangitis and cholangiocarcinoma
Stephanie Seah, Ged Ridgway, Gary Woodward, Marija Mavar, Carlos Ferreira, Andrea Borghetto, John Connell, Matt Kelly, Michael Brady, Rajarshi Banerjee
AB065. P-36. Debio 1347 in patients with cholangiocarcinoma harboring an FGFR gene alteration: preliminary results
Matthew C. H. Ng, Lipika Goyal, Yung-Jue Bang, Do-Youn Oh, Tsu-Yi Chao, James M. Cleary, Martin Henner Voss, Funda Meric-Bernstam, Gopa Iyer, Rebecca Suk Heist, Nobuya Ishii, Yulia Kirpicheva, Anna Pokorska-Bocci, Anne Vaslin, Youyou Hu, Claudio Zanna, David Hyman, Keith Flaherty
AB066. P-37. Epidemiology study of extrahepatic cholangiocarcinoma in Korea
Dong Uk Kim, Tae Hoon Lee, Sang Hyub Lee, Young Koog Cheon
AB067. P-38. Microbial analysis of gallstones and gallbladder tissue by MALDI-TOF in patients with symptomatic gallstones
Dimple Kalsi, Usha Dutta, Priyanka Popli, Pallab Ray, Lileswar Kaman, Divya Dahiya, Arunanshu Behera, Pankaj Sharma, Harshal Mandavdhare, Vishal Sharma
AB068. P-39. Comparison of selective internal radiation therapy (SIRT) versus sorafenib in patients with locally advanced hepatocellular carcinoma in Mongolia: a subgroup analysis of SIRveNIB study
Ariunaa Khasbazar

Disclosure:

The supplement “3rd Asia-Pacific Cholangiocarcinoma Conference”was commissioned by the editorial office, Hepatobiliary Surgery and Nutrition without any sponsorship or funding. Flavio Rocha and Li-Tzong Chen served as the unpaid Guest Editors for the supplement.